Cue Biopharma insider reports initial holdings

Cue Biopharma, Inc. filed an initial Form 3 showing that Chief Legal Compliance Officer and Corporate Secretary Ray Sumita holds 54,589 shares of common stock directly.

Rhea-AI Filing Summary

Cue Biopharma, Inc. filed an initial Form 3 showing that Chief Legal Compliance Officer and Corporate Secretary Ray Sumita holds 54,589 shares of common stock directly. The filing also reports a stock option covering 109,179 shares of common stock at an exercise price of $30.42 per share, expiring on May 1, 2036.

According to the footnote, this stock option becomes exercisable in equal quarterly installments over four years measured from May 1, 2026, meaning vesting is spread over that period rather than all at once.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Ray Sumita

Role Chief Legal Compliance Officer

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 109,179 contracts (Direct); Common Stock — 54,589 shares (Direct)

Footnotes (1)

1. F1. The stock option becomes exercisable in equal, quarterly installments over four years measured from May 1, 2026.

Key Figures

Direct common shares: 54,589 shares Option underlying shares: 109,179 shares Option exercise price: $30.42/share +1 more

4 metrics

Direct common shares 54,589 shares Common Stock held directly by Ray Sumita

Option underlying shares 109,179 shares Underlying Common Stock for stock option

Option exercise price $30.42/share Exercise price for the stock option

Option expiration May 1, 2036 Expiration date of the stock option

Key Terms

Form 3, Stock Option (Right to Buy, exercise price, expiration date, +1 more

5 terms

Form 3 regulatory

"Cue Biopharma, Inc. filed an initial Form 3 showing that..."

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Stock Option (Right to Buy financial

"The filing also reports a stock option covering 109,179 shares..."

exercise price financial

"at an exercise price of $30.42 per share, expiring on May 1, 2036."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"The option expires on May 1, 2036 and represents a right to buy shares..."

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vests quarterly financial

"becomes exercisable in equal quarterly installments over four years..."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Cue Biopharma (CUE) disclose in this Form 3 for Ray Sumita?

Cue Biopharma reports that Chief Legal Compliance Officer Ray Sumita holds 54,589 common shares and a stock option for 109,179 shares at $30.42. The option expires May 1, 2036 and vests quarterly over four years starting May 1, 2026.

How many Cue Biopharma (CUE) common shares does Ray Sumita hold?

Ray Sumita is reported to hold 54,589 shares of Cue Biopharma common stock directly. This figure reflects his ownership position as shown in the initial Form 3 filing as of the reported date, separate from additional shares underlying stock options.

What are the key terms of Ray Sumita’s stock options in Cue Biopharma (CUE)?

The filing lists a stock option for 109,179 Cue Biopharma common shares with a $30.42 exercise price per share. The option expires on May 1, 2036 and represents a right to buy shares if exercised under the vesting schedule described.

How do Ray Sumita’s Cue Biopharma (CUE) stock options vest?

The stock option becomes exercisable in equal quarterly installments over four years measured from May 1, 2026. This means portions of the 109,179 underlying shares become available to exercise each quarter until the full grant is vested over the four-year period.

What is the purpose of this Form 3 related to Cue Biopharma (CUE)?

This Form 3 serves as an initial statement of beneficial ownership for officer Ray Sumita. It discloses his direct holdings of 54,589 common shares and a stock option over 109,179 shares, providing baseline insider ownership information for regulatory and investor transparency.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 05:47 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ray Sumita

(Last) (First) (Middle)

C/O CUE BIOPHARMA, INC.

40 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/01/2026

3. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)	X	Other (specify below)
	Chief Legal Compliance Officer		Corporate Secretary

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	54,589	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	05/01/2036	Common Stock	109,179	$30.42	D

Explanation of Responses:

1. The stock option becomes exercisable in equal, quarterly installments over four years measured from May 1, 2026.

	/s/ Sumita Ray	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)